The saga of Sun Pharma's protracted battle to acquire control of Israel's Taro Pharma seems to be approaching its final hours. Sun, in a last ditch attempt at an early resolution has proposed two options. The first involves a 22 per cent premium to its earlier offer, which will cost Sun $45 million or more.
